Filing Flows › Boston Scientific (BSX) › Interventional Cardiology & Vascular Therapies revenue
Boston Scientific (BSX) Interventional Cardiology & Vascular Therapies revenue by quarter
Boston Scientific's Interventional Cardiology & Vascular Therapies revenue was $1.3B in Q3 2026 (third quarter 2026), -5% from Q2 2026. Over the last 6 quarters it ranged from $686M (Q3 2025) to $1.3B (Q2 2026).
| Quarter | Interventional Cardiology & Vascular Therapies revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.3B | -5% | +86% |
| Q2 2026 | $1.3B | +7% | +82% |
| Q1 2026 | $1.2B | +81% | +78% |
| Q3 2025 | $686M | -6% | — |
| Q2 2025 | $731M | +5% | — |
| Q1 2025 | $697M | — | — |
Q3 2026 at a glance
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Boston Scientific's Interventional Cardiology & Vascular Therapies revenue?
Boston Scientific's Interventional Cardiology & Vascular Therapies revenue was $1.3B in Q3 2026 (third quarter 2026), -5% from Q2 2026.
How has Boston Scientific's Interventional Cardiology & Vascular Therapies revenue changed?
Over the last 6 quarters it ranged from $686M (Q3 2025) to $1.3B (Q2 2026).